NEW YORK, November 6, 2025 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies for oncology and autoimmune diseases, announced its third-quarter 2025 results and pipeline progress. The company highlighted promising preclinical data for INB-619, expansion of its INB-100 Phase 1 trial to new academic sites, and a strengthened financial position marked by a reduced net loss of $3.9 million and cash reserves of $10.7 million. These milestones affirm IN8bio’s scientific and operational momentum toward next-generation immunotherapies that redefine immune modulation and disease control.
Science Significance
IN8bio continues to advance the science of gamma-delta T cell immunotherapy, a frontier that bridges innate and adaptive immunity. The company’s INB-619 program, a CD19-targeting γδ T cell engager, demonstrated potency comparable to FDA-approved therapies while exhibiting minimal cytokine release, a key safety improvement over traditional CD3-based T cell engagers. This discovery suggests a breakthrough pathway for deep B-cell depletion in autoimmune and hematologic diseases. Additionally, INB-100, its donor-derived allogeneic T cell therapy for leukemia patients undergoing stem-cell transplantation, continues to expand across top U.S. cancer centers, reinforcing the company’s position in cutting-edge cellular immunology research.
Regulatory Significance
IN8bio’s clinical expansion underscores its strong adherence to Good Clinical Practice (GCP) and FDA regulatory standards. The inclusion of The Ohio State University’s James Comprehensive Cancer Center in the INB-100 Phase 1 trial broadens patient access and ensures regulatory compliance across diverse jurisdictions. The company’s focus on cGxP governance, ethical enrollment, and data integrity aligns with the FDA’s evolving framework for cell and gene therapies. With multiple data presentations scheduled at the Society for Neuro-Oncology (SNO) and the American Society of Hematology (ASH) meetings, IN8bio is advancing toward pivotal clinical discussions with regulators on the translational readiness of its γδ platform.
Business Significance
Advertisement
Financially, IN8bio delivered measurable cost optimization and improved fiscal control. R&D expenses decreased to $2.1 million, and general and administrative costs fell to $1.9 million, reflecting disciplined management following 2024’s pipeline prioritization. The company’s net loss halved year-over-year, supported by a cash position of $10.7 million, allowing for continued advancement of high-potential programs. CEO William Ho emphasized the company’s strategic focus on the DeltEx™ platform, designed to deliver differentiated γδ T cell therapies that outperform conventional T cell approaches. This financial and operational strength positions IN8bio to sustain clinical acceleration and investor confidence.
Patients’ Significance
For patients facing relapsed leukemia, glioblastoma, or autoimmune diseases, IN8bio’s therapies represent a transformative new class of immunotherapy. Unlike conventional approaches, γδ T cells uniquely identify diseased cells independent of MHC presentation, enabling broader applicability across genetic backgrounds. INB-619’s cytokine-sparing profile may reduce serious immune reactions, improving tolerability and dosing flexibility. Meanwhile, INB-100 and INB-200/400 aim to restore immune balance and enhance long-term remission, offering hope for patients with limited treatment options. Each program underscores IN8bio’s mission to translate cellular biology into tangible patient benefits.
Policy Significance
The company’s progress aligns with global health-policy objectives promoting innovation in cell and gene therapy under robust cGxP oversight. As regulators refine frameworks for next-generation biologics, IN8bio’s compliance-driven development offers a model for safe and ethical clinical translation. Its academic collaborations illustrate the benefits of public-private partnerships that accelerate medical breakthroughs while ensuring equitable access. The company’s work contributes to shaping future policy around immunotherapy standardization, manufacturing scalability, and clinical data transparency, essential pillars of the modern biopharma ecosystem.
IN8bio’s Q3 2025 report demonstrates steady progress in scientific innovation, regulatory execution, and financial discipline. By expanding its clinical footprint and unveiling promising γδ T cell data, the company continues to chart a course toward redefining how immune cell therapies are designed and delivered. Supported by a sound balance sheet and a clear strategic vision, IN8bio is poised to translate its DeltEx™ platform into real-world therapeutic impact — a step forward for both the science of immunotherapy and the patients it aims to serve.
Source: IN8bio, Inc press release
